NewAmsterdam Pharma Company N.V.
$33.82
▲
0.55%
2026-04-21 08:20:00
www.newamsterdampharma.com
NGM: NAMS
Explore NewAmsterdam Pharma Company N.V. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3.89 B
Current Price
$33.82
52W High / Low
$42 / $15.82
Stock P/E
—
Book Value
$5.97
Dividend Yield
—
ROCE
-33.02%
ROE
-28.29%
Face Value
—
EPS
$-1.72
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
100
Beta
0.13
Debt / Equity
0.03
Current Ratio
7.88
Quick Ratio
7.88
Forward P/E
-25.43
Price / Sales
177.6
Enterprise Value
$3.36 B
EV / EBITDA
-14.9
EV / Revenue
149.34
Rating
Strong Buy
Target Price
$49.61
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Inovio Pharmaceuticals, Inc. | $1.18 | — | $96.69 M | — | -283.35% | -1.83% | $2.98 / $1.03 | $0.35 |
| 2. | Ocular Therapeutix, Inc. | $9.52 | — | $2.09 B | — | -35.66% | -54.85% | $16.44 / $6.23 | $3.03 |
| 3. | IDEAYA Biosciences, Inc. | $33.6 | — | $2.95 B | — | -15.17% | -10.92% | $39.28 / $16.07 | $11.65 |
| 4. | MiMedx Group, Inc. | $3.25 | 10.44 | $507.35 M | — | 22.95% | 21.61% | $7.99 / $3.31 | $1.73 |
| 5. | Cingulate Inc. | $6.03 | — | $66.77 M | — | -418.81% | -4.51% | $11.89 / $3.2 | $0.35 |
| 6. | Kura Oncology, Inc. | $9.78 | — | $863.87 M | — | -48.86% | -94.82% | $12.49 / $5.45 | $1.98 |
| 7. | Coeptis Therapeutics Holdings, Inc. | $15.54 | — | $91.17 M | — | -90.67% | -1.37% | $21.41 / $6.26 | $2.36 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.03 M | 0.35 M | 19.14 M | 2.98 M | 12.77 M | — |
| Operating Profit | -65.98 M | -55.14 M | -35.63 M | -68.92 M | -46.43 M | — |
| Net Profit | -74.92 M | -72 M | -17.36 M | -39.53 M | -92.18 M | — |
| EPS in Rs | -0.65 | -0.63 | -0.15 | -0.34 | -0.8 | -0.18 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 22.5 M | 45.56 M | 14.09 M | 102.69 M |
| Operating Profit | -225.68 M | -176.29 M | -182.97 M | -3.56 M |
| Net Profit | -203.82 M | -241.6 M | -176.94 M | -22.63 M |
| EPS in Rs | -1.77 | -2.1 | -1.54 | -0.2 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 769.28 M | 864.62 M | 347.1 M | 478.5 M |
| Total Liabilities | 85.85 M | 107.12 M | 58.7 M | 48.43 M |
| Equity | 683.43 M | 757.5 M | 288.39 M | 430.07 M |
| Current Assets | 675.7 M | 863.41 M | 346.79 M | 477.98 M |
| Current Liabilities | 85.79 M | 106.92 M | 49.9 M | 36.06 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -147.78 M | -158.56 M | -141.22 M | 10.66 M |
| Investing CF | -174.92 M | -62.85 M | -0.02 M | -0.22 M |
| Financing CF | 29.52 M | 659.51 M | 8.91 M | 391.9 M |
| Free CF | -148.03 M | -159.24 M | -141.24 M | 10.44 M |
| Capex | -0.25 M | -0.67 M | -0.02 M | -0.22 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 223.37% | -86.28% | — | — |
| Earnings Growth % | -36.54% | -681.73% | — | — |
| Profit Margin % | -530.25% | -1255.76% | -22.04% | — |
| Operating Margin % | -386.91% | -1298.56% | -3.46% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -386.66% | -1298.21% | -21.75% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.